Compared to no-antibody controls, the addition of 5 μg/mL anti-CD44 resulted in significantly more apoptotic AML cells using three different cytarabine concentrations (Figure 4a): a 1.39–1.66-fold increase in apoptotic OCI-AML3 cells and a 1.44–1.8-fold increase in apoptotic KG1a cells. This evidence concerns the gene CD44 and acute myeloid leukemia.